Adenosine A₂A agonist improves lung function during ex vivo lung perfusion

Area of Science:

• Cardiovascular and Respiratory System Science
• Transplantation Immunology
• Regenerative Medicine

Background:

• Ex vivo lung perfusion (EVLP) is a technique to assess and repair marginal donor lungs for transplantation.
• Adenosine protects against pulmonary ischemia-reperfusion (IR) injury via its A(2A) receptor.

Purpose of the Study:

• To investigate if combining EVLP with an adenosine A(2A) receptor agonist enhances lung quality.
• To determine if this combination increases the utilization of donor lungs for transplantation.

Main Methods:

• Eight bilateral pig lungs underwent EVLP after 14 hours of cold storage.
• Control lungs (n=4) received standard EVLP solution; treated lungs (n=4) received EVLP with an A(2A) receptor agonist (CGS21680).
• Lung histology, cytokine levels, gas exchange, and pulmonary function were compared.

Main Results:

• Treated lungs showed significantly reduced edema (wet-dry weight ratio) and lower interferon-gamma (IFN-γ) levels.
• Improved oxygenation index and mean airway pressure were observed in the treated group.
• Other inflammatory cytokine levels were reduced but not statistically significant.

Conclusions:

• Adenosine A(2A) agonist combined with EVLP attenuates inflammation and improves function in injured lungs.
• This strategy holds potential for enhancing donor lung quality.
• The combination may increase the availability of donor lungs for transplantation.